Fresenius Medical Care AG & Co. KGaA $FMS Shares Bought by ABC Arbitrage SA

ABC Arbitrage SA lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 1,136.0% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 249,800 shares of the company’s stock after purchasing an additional 229,589 shares during the quarter. ABC Arbitrage SA’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $5,950,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. CIBC Private Wealth Group LLC grew its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 398.2% in the third quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock valued at $36,000 after purchasing an additional 1,103 shares in the last quarter. Group One Trading LLC purchased a new position in Fresenius Medical Care AG & Co. KGaA in the 3rd quarter valued at approximately $74,000. EverSource Wealth Advisors LLC grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 141.8% in the second quarter. EverSource Wealth Advisors LLC now owns 2,906 shares of the company’s stock worth $83,000 after acquiring an additional 1,704 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Fresenius Medical Care AG & Co. KGaA in the third quarter worth $120,000. Finally, Russell Investments Group Ltd. increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 21.3% during the second quarter. Russell Investments Group Ltd. now owns 5,096 shares of the company’s stock worth $146,000 after acquiring an additional 896 shares during the period. Hedge funds and other institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Stock Down 1.2%

Shares of NYSE FMS opened at $21.76 on Tuesday. The business has a 50-day moving average of $22.64 and a two-hundred day moving average of $23.36. The company has a market capitalization of $12.15 billion, a price-to-earnings ratio of 11.45, a price-to-earnings-growth ratio of 3.78 and a beta of 0.81. Fresenius Medical Care AG & Co. KGaA has a 1 year low of $20.02 and a 1 year high of $30.46. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.20 and a quick ratio of 0.86.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its earnings results on Tuesday, March 31st. The company reported $1.05 earnings per share for the quarter. The business had revenue of $5.34 billion for the quarter. Fresenius Medical Care AG & Co. KGaA had a return on equity of 8.90% and a net margin of 4.88%. On average, analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 2.35 earnings per share for the current fiscal year.

Fresenius Medical Care AG & Co. KGaA Increases Dividend

The business also recently disclosed an annual dividend, which will be paid on Monday, June 8th. Stockholders of record on Friday, May 22nd will be given a dividend of $0.8716 per share. The ex-dividend date is Friday, May 22nd. This represents a dividend yield of 385.0%. This is a boost from Fresenius Medical Care AG & Co. KGaA’s previous annual dividend of $0.79. Fresenius Medical Care AG & Co. KGaA’s payout ratio is presently 30.00%.

Analyst Upgrades and Downgrades

FMS has been the subject of a number of recent research reports. Citigroup reiterated a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday, April 24th. Jefferies Financial Group cut Fresenius Medical Care AG & Co. KGaA from a “moderate sell” rating to a “strong sell” rating in a research note on Tuesday, February 24th. Erste Group Bank lowered shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 5th. Wall Street Zen cut shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Morgan Stanley reiterated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Wednesday, May 6th. Five analysts have rated the stock with a Hold rating and four have given a Sell rating to the stock. Based on data from MarketBeat.com, Fresenius Medical Care AG & Co. KGaA presently has a consensus rating of “Reduce” and a consensus target price of $28.00.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.